Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 356 followers
Latest posts
Last updated 4 days ago
Invitation to Roche’s Virtual Oncology/SABCS Investor Event
4 days ago
We are pleased to invite investors and analysts to participate in our...
European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
11 days ago
Lunsumio provides high rates of deep and long-lasting responses in third-line and...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer
12 days ago
At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis
20 days ago
The first (FENhance 2) of two pivotal RMS studies met its primary...
Roche to present new data from its broad and innovative haematology portfolio at ASH 2025
26 days ago
Findings further demonstrate the effectiveness of Roche’s approved medicines in advancing treatment...
Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus
27 days ago
Phase III ALLEGORY study met primary and all key secondary endpoints with...
Roche purchases shares in tender offer for 89bio, Inc
about 1 month ago
Basel, 30 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised
about 1 month ago
Group sales grew by 7%1 at constant exchange rates (CER; 2% in...
Reminder: Invitation to Roche’s 3rd Quarter Sales 2025 Presentation
about 1 month ago
Roche will publish its Sales for the 3rd Quarter of 2025 prior...
Reminder: Invitation to Roche’s 3rd Quarter Sales 2025 Presentation
about 1 month ago
Roche will publish its Sales for the 3rd Quarter of 2025 prior...
Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
about 1 month ago
Tecentriq reduced the risk of death by 41% and the risk of...
FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
about 1 month ago
FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as...